DK0888384T3 - Fusionspolypeptid til påvirkning af vekselvirkninger mellem proteiner - Google Patents
Fusionspolypeptid til påvirkning af vekselvirkninger mellem proteinerInfo
- Publication number
- DK0888384T3 DK0888384T3 DK97919258T DK97919258T DK0888384T3 DK 0888384 T3 DK0888384 T3 DK 0888384T3 DK 97919258 T DK97919258 T DK 97919258T DK 97919258 T DK97919258 T DK 97919258T DK 0888384 T3 DK0888384 T3 DK 0888384T3
- Authority
- DK
- Denmark
- Prior art keywords
- proteins
- fusion polypeptide
- influence interactions
- interactions
- influence
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 230000003993 interaction Effects 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 230000004927 fusion Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5412—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19608813A DE19608813C2 (de) | 1996-03-07 | 1996-03-07 | Konjugat zur Beeinflussung von Wechselwirkungen zwischen Proteinen |
| PCT/DE1997/000458 WO1997032891A2 (fr) | 1996-03-07 | 1997-03-07 | Conjugue pour influer sur les interactions entre des proteines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0888384T3 true DK0888384T3 (da) | 2003-03-24 |
Family
ID=7787490
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK97919258T DK0888384T3 (da) | 1996-03-07 | 1997-03-07 | Fusionspolypeptid til påvirkning af vekselvirkninger mellem proteiner |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7112436B1 (fr) |
| EP (1) | EP0888384B1 (fr) |
| JP (1) | JP4301575B2 (fr) |
| AT (1) | ATE229542T1 (fr) |
| DE (2) | DE19608813C2 (fr) |
| DK (1) | DK0888384T3 (fr) |
| ES (1) | ES2188935T3 (fr) |
| PT (1) | PT888384E (fr) |
| WO (1) | WO1997032891A2 (fr) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6217858B1 (en) | 1997-02-11 | 2001-04-17 | Hadasit & Medical Research Services & Development Company, Ltd. | Pharmaceutical composition for treating hepatitis B virus (HBV) infection |
| IL122818A0 (en) * | 1997-07-10 | 1998-08-16 | Yeda Res & Dev | Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof |
| CA2447632C (fr) * | 2000-06-16 | 2011-08-02 | Asterion Limited | Agoniste d'une proteine hybride comprenant une partie se liant a une hotmone de croissance et un domaine externe d'un recepteur d'hormone de croissance |
| DE10107737A1 (de) * | 2001-02-16 | 2002-09-05 | S Rose John Christian Albrecht | Verwendung eines Konjugats aus IL-6 und einem IL-6 Rezeptor zur Tumortherapie |
| EP1499332A4 (fr) * | 2002-04-29 | 2006-12-06 | Hadasit Med Res Service | Compositions et methodes de traitement du cancer avec un agent oncolytique viral |
| EP1400587A1 (fr) * | 2002-09-19 | 2004-03-24 | MainGen Biotechnologie GmbH | Utilisation de polypeptide de fusion pour l'obtention de cellules souches pluripontentes non embryonales |
| IL161672A0 (en) | 2004-04-29 | 2004-09-27 | Yeda Res & Dev | Compositions and methods for therapy of chemotherapy-induced neuropathy |
| EP1598364A1 (fr) * | 2004-05-21 | 2005-11-23 | AGIRx Limited | Recepteur chimérique soluble hyper IL-11 et son utilisation |
| DE102004033122A1 (de) * | 2004-07-08 | 2006-02-09 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Vorrichtung und Verfahren zur Analyse von Wechselwirkungen zwischen Biomolekülen |
| CA2608474C (fr) * | 2005-05-17 | 2019-11-12 | University Of Connecticut | Compositions et methodes d'immunomodulation d'un organisme |
| EP2335714B1 (fr) | 2005-06-16 | 2014-02-26 | Hadasit Medical Research Services And Development Ltd. | Un complexe comprenant IL-6/récepteur soluble de IL-6 pour le traitement de l'insuffisance rénale |
| EP1777294A1 (fr) * | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Le domaine sushi de IL-15Ralpha comme enhancer sélectif et efficace de l'action de f IL-15 grâce à IL-15Rbeta/gamma, et l' hyperagoniste (IL15Ralpha sushi -IL15) comme protéine fusion |
| CA2636111C (fr) | 2006-01-13 | 2018-04-03 | The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health | Genes il-15 et il-15r-alpha a codon optimise destines a l'expression dans les cellules mammaliennes |
| US20090098529A1 (en) * | 2006-10-16 | 2009-04-16 | Nanhai Chen | Methods for attenuating virus strains for diagnostic and therapeutic uses |
| WO2009002562A2 (fr) | 2007-06-27 | 2008-12-31 | Marine Polymer Technologies, Inc. | Complexes d'il-15 et il-15r alpha et leurs utilisations |
| EP2185583A2 (fr) * | 2007-08-03 | 2010-05-19 | Asterion Limited | Facteur de stimulation des colonies de granulocytes |
| GB0715213D0 (en) * | 2007-08-06 | 2007-09-12 | Asterlon Ltd | Igf-1 |
| WO2009069133A2 (fr) * | 2007-11-28 | 2009-06-04 | Hadasit Medical Research Services And Development Ltd. | Procédés de traitement de lésion tissulaire induite par un rayonnement ou une chimiothérapie |
| EP2300023A2 (fr) * | 2008-05-16 | 2011-03-30 | Genelux Corporation | Microorganismes pour la prévention et le traitement de néoplasmes accompagnant une thérapie cellulaire |
| WO2010081738A1 (fr) * | 2009-01-16 | 2010-07-22 | Agirx Limited | Compositions vaccinales |
| EP3135294B1 (fr) | 2009-08-14 | 2020-06-03 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Utilisation d'il-15 pour accroître la production thymique et traiter la lymphopénie |
| WO2011151716A1 (fr) | 2010-06-04 | 2011-12-08 | Lupin Limited | Procédé de purification d'il-11 humaine recombinante |
| EP2832856A4 (fr) | 2012-03-29 | 2016-01-27 | Chugai Pharmaceutical Co Ltd | Anticorps anti-lamp5 et son utilisation |
| PL2986312T3 (pl) | 2013-04-19 | 2022-04-19 | Cytune Pharma | Oparte na cytokinie leczenie z ograniczeniem zespołu przesiąkania naczyniowego |
| EP2915569A1 (fr) | 2014-03-03 | 2015-09-09 | Cytune Pharma | Procédé de purification de conjugués à base Il -15/IL-15Ralpha |
| EP2992898A1 (fr) | 2014-09-04 | 2016-03-09 | Klinikum rechts der Isar der Technischen Universität München | Adjuvant pour lymphocyte T utiles pour la vaccination thérapeutique ou prophylactique |
| CN110055224B (zh) * | 2019-04-03 | 2023-06-30 | 深圳市体内生物医药科技有限公司 | 一种基因修饰的免疫细胞及其制备方法和应用 |
| EP3875111A1 (fr) | 2020-03-05 | 2021-09-08 | Poznan University Of Medical Sciences | Composition de vaccin contre le cancer de cellules souches |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| GB9324807D0 (en) | 1993-12-03 | 1994-01-19 | Cancer Res Campaign Tech | Tumour antibody |
| CA2196085C (fr) | 1994-07-29 | 2002-12-10 | Hing C. Wong | Complexes bases sur le complexe majeur d'histocompabilite et leurs applications |
-
1996
- 1996-03-07 DE DE19608813A patent/DE19608813C2/de not_active Expired - Fee Related
-
1997
- 1997-03-07 DE DE59708952T patent/DE59708952D1/de not_active Expired - Lifetime
- 1997-03-07 AT AT97919258T patent/ATE229542T1/de active
- 1997-03-07 US US09/142,471 patent/US7112436B1/en not_active Expired - Fee Related
- 1997-03-07 DK DK97919258T patent/DK0888384T3/da active
- 1997-03-07 EP EP97919258A patent/EP0888384B1/fr not_active Expired - Lifetime
- 1997-03-07 ES ES97919258T patent/ES2188935T3/es not_active Expired - Lifetime
- 1997-03-07 JP JP53135697A patent/JP4301575B2/ja not_active Expired - Fee Related
- 1997-03-07 WO PCT/DE1997/000458 patent/WO1997032891A2/fr active IP Right Grant
- 1997-03-07 PT PT97919258T patent/PT888384E/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0888384B1 (fr) | 2002-12-11 |
| US7112436B1 (en) | 2006-09-26 |
| EP0888384A2 (fr) | 1999-01-07 |
| ATE229542T1 (de) | 2002-12-15 |
| WO1997032891A3 (fr) | 1998-02-05 |
| DE59708952D1 (de) | 2003-01-23 |
| WO1997032891A2 (fr) | 1997-09-12 |
| PT888384E (pt) | 2003-04-30 |
| DE19608813A1 (de) | 1997-09-18 |
| ES2188935T3 (es) | 2003-07-01 |
| JP2000506014A (ja) | 2000-05-23 |
| DE19608813C2 (de) | 1998-07-02 |
| JP4301575B2 (ja) | 2009-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0888384T3 (da) | Fusionspolypeptid til påvirkning af vekselvirkninger mellem proteiner | |
| BR0212256A (pt) | Proteìnas de fusão de transferrina modificadas | |
| EA199900575A1 (ru) | Композиции на основе слитого белка ов и способы их применения | |
| WO2000018921A3 (fr) | Peptides synthetiques possedant une affinite pour le recepteur de fgf | |
| WO1999002711A3 (fr) | Proteines de fusion avec une liaison de region charniere d'immunoglobuline | |
| PL336306A1 (en) | Proteinous fusions of tgf-beta ii type receptor with a constant immunoglobulin area | |
| SE9901379D0 (sv) | Receptor structures | |
| PT1121382E (pt) | Proteinas de fusao do interferao beta e as respectivas utilizacoes | |
| DK1088084T3 (da) | Erythropoietin analog-humant serumalbumin fusionsprotein | |
| BR0314092A (pt) | proteìnas de fusão de transferrina modificadas | |
| WO2003102157A3 (fr) | Bibliotheques de phages et anticorps synthetiques | |
| DK1140173T4 (da) | Vaskulære endothelcellevækstfaktorantagonister og anvendelser deraf | |
| UA89017C2 (uk) | ЛЮДСЬКЕ АНТИТІЛО, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ЛЮДСЬКИМ TNFSF13b | |
| WO2000018932A3 (fr) | Antagonistes a base de recepteurs, modes d'elaboration et d'utilisation | |
| DK1017715T3 (da) | Kimært polypeptid der omfatter fragment B af shiga-toksin og peptider af terapeutisk interesse | |
| SI1346034T1 (sl) | POLIPEPTID PROTEAZE, KI CEPI VON WILLEBRANDOV FAKTOR (vWF), NUKLEINSKA KISLINA, KI KODIRA POLIPEPTID, IN UPORABA POLIPEPTIDA | |
| DK258789D0 (da) | Peptider, der blokerer bindingen af hiv-1 til cd4 receptorproteinet | |
| WO1998057983A3 (fr) | Proteine de mammifere de type facteur de croissance nerveuse | |
| PT625157E (pt) | Epitopes p1a1 e p1a2 da gpiiia da plaqueta sua preparacao e utilizacao | |
| DK0635025T3 (da) | Fremgangsmåde til fremstilling af modificerede proteiner | |
| DE69634077D1 (de) | Haemophilus adhäsionsproteinen | |
| DK0506923T3 (da) | Et collagenbindende protein samt fremstilling deraf | |
| ATE452650T1 (de) | Transferrin-fusionsproteinbibliotheken | |
| ATE385805T1 (de) | Neue peptide | |
| EA200400392A1 (ru) | Связывающий каспазу-8 белок, его получение и применение |